Prova Education

New Horizons in Ulcerative Colitis

New Horizons in Ulcerative Colitis
RestartResume

Investigational agents and new mechanisms of action promise to overcome the challenges of treatment non-response in ulcerative colitis.  

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Ulcerative Colitis (UC) patients may experience a wide variety of symptoms, and there are well-documented gaps in individual patient care. This article reviews the mechanisms of action for newer investigational therapies that may offer the potential to optimize induction and maintenance of remission in patients with UC, as well as review the emergence of biomarkers that may help us personalize treatment in patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:

    Christina  Ha, MD, FACG, AGAF
    Associate Professor of Medicine
    Cedars-Sinai IBD Center
    Los Angeles, CA

    Speakers Bureau: AbbVie, Genentech, IBD Remedy, Janssen, Medical Speakers Network, Pfizer, Salix, Takeda

    David T. Rubin, MD  
    Professor of Medicine
    University of Chicago Medicine
    Chicago, IL 

    Consulting Fees:  AbbVie, Abgenomics, Allergan, Inc., Biomica, Boehringer Ingelheim, Ltd., Bristol-Myers Squibb, Celgene Corp./Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Glenmark Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceuticals, Lilly, Mahana Therapeutics, Medtronic, Narrow River Mgmt, Pfizer, Prometheus Laboratories, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions, Inc.
    Grant Support: AbbVie, Genentech/Roche, Janssen Pharmaceuticals, Prometheus Laboratories, Shire, Takeda
    Other:  GoDuRn, LLC. (Co-Founder)

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian McDonough, MD, FAAFP has nothing to disclose.
    • William A. Mencia, MD has nothing to disclose.
    • Tricia O’ Leary has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Compare the mechanisms of action for novel anti-integrin antibodies that may offer the potential to optimize induction and maintenance of remission patients with ulcerative colitis
    • Devise real-world strategies to overcome barriers to optimal care of patients with ulcerative colitis, such as the limited effectiveness of traditional biologic therapy and ongoing challenges in defining treatment targets
  • Target Audience

    This activity is designed to meet the educational needs of Gastroenterologist, and Primary Care physicians, Pediatricians and NP/PA who treat patients with ulcerative colitis.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Genentech.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free